WO2023213198A1 - Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant - Google Patents

Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant Download PDF

Info

Publication number
WO2023213198A1
WO2023213198A1 PCT/CN2023/089862 CN2023089862W WO2023213198A1 WO 2023213198 A1 WO2023213198 A1 WO 2023213198A1 CN 2023089862 W CN2023089862 W CN 2023089862W WO 2023213198 A1 WO2023213198 A1 WO 2023213198A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
saturated
cancer
substituted
partially unsaturated
Prior art date
Application number
PCT/CN2023/089862
Other languages
English (en)
Chinese (zh)
Inventor
阳怀宇
叶阳亮
李俊男
莫奕青
晏雨茜
梅良和
张乾森
沈菊文
钱林艺
Original Assignee
华东师范大学
苏州阿尔脉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东师范大学, 苏州阿尔脉生物科技有限公司 filed Critical 华东师范大学
Publication of WO2023213198A1 publication Critical patent/WO2023213198A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le composé (I) suivant ou un sel, ester, isomère optique, stéréoisomère ou métabolite pharmaceutiquement acceptable de celui-ci, et une composition pharmaceutique contenant le composé selon la présente invention. L'invention concerne en outre une utilisation du composé selon la présente invention en tant qu'activateur d'un canal ionique potassique TREK-1, et une utilisation dans la réduction et/ou l'élimination de la douleur, et une utilisation du composé selon la présente invention dans la préparation de médicaments analgésiques. La présente invention concerne également une méthode de traitement de maladies associées au canal ionique potassique TREK-1.
PCT/CN2023/089862 2022-05-04 2023-04-21 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant WO2023213198A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210477484.3 2022-05-04
CN202210477484 2022-05-04

Publications (1)

Publication Number Publication Date
WO2023213198A1 true WO2023213198A1 (fr) 2023-11-09

Family

ID=88575128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/089862 WO2023213198A1 (fr) 2022-05-04 2023-04-21 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant

Country Status (2)

Country Link
CN (1) CN117003756A (fr)
WO (1) WO2023213198A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270590A (zh) * 1997-07-22 2000-10-18 英国阿斯特拉药品有限公司 新的化合物
CN1334816A (zh) * 1998-12-04 2002-02-06 阿斯特拉曾尼卡有限公司 新的三唑并(4,5－d)嘧啶化合物
US20080188483A1 (en) * 2005-03-15 2008-08-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
CN103275087A (zh) * 2013-06-28 2013-09-04 南京工业大学 一种三氮唑并嘧啶类衍生物及其制备方法
CN103864794A (zh) * 2012-12-07 2014-06-18 上海科胜药物研发有限公司 一种制备抗血小板凝集药物替卡格雷的方法
CN104672242A (zh) * 2015-02-09 2015-06-03 扬子江药业集团有限公司 一种替格瑞洛的制备方法
US20170197965A1 (en) * 2014-06-12 2017-07-13 Pfizer Limited Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity
CN109689061A (zh) * 2016-09-09 2019-04-26 列日大学 三唑并(4,5-d)嘧啶衍生物用于预防和治疗细菌感染的新用途
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN111386271A (zh) * 2018-02-14 2020-07-07 列日大学 用于预防和治疗细菌感染的嘧啶衍生物
CN114432315A (zh) * 2020-11-05 2022-05-06 华东师范大学 一种预防、治疗疼痛的化合物及其应用

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1270590A (zh) * 1997-07-22 2000-10-18 英国阿斯特拉药品有限公司 新的化合物
CN1334816A (zh) * 1998-12-04 2002-02-06 阿斯特拉曾尼卡有限公司 新的三唑并(4,5－d)嘧啶化合物
US20080188483A1 (en) * 2005-03-15 2008-08-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
CN103864794A (zh) * 2012-12-07 2014-06-18 上海科胜药物研发有限公司 一种制备抗血小板凝集药物替卡格雷的方法
CN103275087A (zh) * 2013-06-28 2013-09-04 南京工业大学 一种三氮唑并嘧啶类衍生物及其制备方法
US20170197965A1 (en) * 2014-06-12 2017-07-13 Pfizer Limited Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity
CN104672242A (zh) * 2015-02-09 2015-06-03 扬子江药业集团有限公司 一种替格瑞洛的制备方法
CN109689061A (zh) * 2016-09-09 2019-04-26 列日大学 三唑并(4,5-d)嘧啶衍生物用于预防和治疗细菌感染的新用途
CN111386271A (zh) * 2018-02-14 2020-07-07 列日大学 用于预防和治疗细菌感染的嘧啶衍生物
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN114432315A (zh) * 2020-11-05 2022-05-06 华东师范大学 一种预防、治疗疼痛的化合物及其应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry 10 June 2019 (2019-06-10), ANONYMOUS: "1,2-Cyclopentanediol, 3-(2-bromoethoxy)-5-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3S,5R)- (CA INDEX NAME)", XP093105723, retrieved from STNext Database accession no. 2307234-01-9 *
DATABASE Registry 22 December 2021 (2021-12-22), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-5-(2-iodoethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105720, retrieved from STNext Database accession no. 2750168-80-8 *
DATABASE Registry 26 June 2020 (2020-06-26), ANONYMOUS: "1,2,3-Cyclopentanetriol, 4-[7-[[(1R)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3R,4R)-rel- (CA INDEX NAME)", XP093105721, retrieved from STNext Database accession no. 2434860-97-4 *
DATABASE Registry. 21 February 2019 (2019-02-21), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(2-propen-1-ylthio)-3H-1,2,3- triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105722, Database accession no. 2271293-30-0 *
ERIC GOFFIN ET AL.: "Synthesis of Ticagrelor Analogues Belonging to 1,2,3-triazolo[4,5-d]pyrimidines and Study of Their Antiplatelet and Antibacterial Activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 208, 23 August 2020 (2020-08-23), XP086345788, DOI: 10.1016/j.ejmech.2020.112767 *
HASSANE SADOU YAYE ET AL.: "Identification of the Major Degradation Pathways of Ticagrelor", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 105, 4 December 2014 (2014-12-04), XP029130906, DOI: 10.1016/j.jpba.2014.11.046 *
ZHONG WANPING, WANG XIPEI, TANG LAN, MAI LIPING, CHEN XIAO-PING, HE GUODONG, ZHENG ZHIJIE, ZHONG SHILONG: "Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography–Tandem Mass Spectrometry", JOURNAL OF ANALYTICAL TOXICOLOGY, PRESTON PUBLICATIONS, INC., US, vol. 40, no. 6, 1 July 2016 (2016-07-01), US , pages 445 - 453, XP093105672, ISSN: 0146-4760, DOI: 10.1093/jat/bkw039 *

Also Published As

Publication number Publication date
CN117003756A (zh) 2023-11-07

Similar Documents

Publication Publication Date Title
BR112021009880A2 (pt) pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos
WO2020259679A1 (fr) Dérivé hétérocyclique azoté à cinq chaînons de pyrimidine, son procédé de préparation et son utilisation pharmaceutique
WO2021169990A1 (fr) Inhibiteurs de kras pour le traitement de cancers
TWI662039B (zh) 用於誘發軟骨生成之化合物及組合物
WO2019134539A1 (fr) Composé de dihydropyrazolone et de pyrimidine, son procédé de préparation et son utilisation
TWI794232B (zh) 激酶抑制劑及其用途
EP4289843A1 (fr) Dérivé de pyridopyrimidinone, son procédé de préparation et son utilisation
TWI793704B (zh) Sos1抑制劑、包含其的藥物組合物及其用途
EP4166549A1 (fr) Composé cyclique spiro aromatique substitué par un isotope et son application
WO2021249519A1 (fr) Dérivé de pyridine-pyrimidine, son procédé de préparation et son utilisation pharmaceutique
WO2021180235A1 (fr) Inhibiteur de l'activateur de l'homologue 2 de zeste et son utilisation
BR112015022092B1 (pt) Derivados de di-hidropiridazina-3,5-diona, seus usos e agente preventivo e/ou terapêutico compreendendo os mesmos
JP2019537592A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
WO2022121813A1 (fr) Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation
WO2023011513A1 (fr) Inhibiteur de shp2, composition pharmaceutique le comprenant et son application
JP2019537581A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN111320633B (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
TW202204351A (zh) 具有大環結構的化合物及其用途
JP2024516317A (ja) Ｓｈｐ２リン酸化酵素阻害剤の調製と応用
WO2020088390A1 (fr) Composés de pyrimidopyrazole utilisés en tant qu'inhibiteurs d'egfr de quatrième génération
CA2958543A1 (fr) Derives de dihydropyridazine-3,5-dione utiles comme inhibiteurs de porteur de phosphate dependant au sodium
WO2023213198A1 (fr) Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
TW201910330A (zh) 磺醯胺類衍生物、其製備方法及其在醫藥上的用途
WO2022237890A1 (fr) Composé à cycle fusionné du type azépine et son utilisation pharmaceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23799185

Country of ref document: EP

Kind code of ref document: A1